GlassScriptPhysician profile
Aneeta J Joseph
NPI 1396108916
$1,400.53
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.95 · 2020: $118 · 2021: $178 · 2022: $224 · 2023: $479 · 2024: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $213.08 | 2022-2024 | Freestyle Libre 3 |
| Amgen INC. | $151.39 | 2020-2024 | Repatha, Otezla, Tepezza |
| Sanofi-Aventis U.S. LLC | $141.22 | 2020-2024 | |
| Corcept Therapeutics | $124.07 | 2021-2024 | Korlym |
| Lilly USA, LLC | $94.88 | 2022-2024 | Jardiance, Zepbound |
| Medtronic, INC. | $88.31 | 2023-2024 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $71.84 | 2021-2023 | Ozempic, Rybelsus |
| Mannkind Corporation | $65.33 | 2023 | Afrezza |
| Dexcom, INC. | $63.30 | 2022-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $43.81 | 2021-2023 | Tepezza |
| Astrazeneca Pharmaceuticals LP | $38.49 | 2022 | |
| Ibsa Pharma INC. | $37.18 | 2021 | |
| Abbvie INC. | $36.19 | 2023-2024 | |
| Insulet Corporation | $35.65 | 2024 | Omnipod |
| Radius Health, INC. | $33.73 | 2022-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $24.29 | 2023 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $23.22 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Averitas Pharma INC. | $22.90 | 2023 | Qutenza |
| Recordati_rare_diseases_inc. | $22.76 | 2023 | Signifor Lar, Isturisa |
| Amarin Pharma, INC. | $17.78 | 2021 | |
| Pfizer INC. | $17.67 | 2023 | |
| Shire North American Group INC | $16.95 | 2019 | |
| Kyowa Kirin, INC. | $16.49 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneeta Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.